Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Soleno Therapeutics Inc (AKA: Capnia )
Profile last edited on: 6/9/2024      CAGE: 72XA4      UEI: DA8ADMFJRDU9

Business Identifier: Proprietary medical gas delivery system to develop therapeutic products for chronic disease
Year Founded
1999
First Award
2015
Latest Award
2018
Program Status
Active (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

203 Redwood Shores Parkway Suite 500
Redwood City, CA 94065
   (650) 213-8444
   info@soleno.life
   www.soleno.life
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

In 2017, the small firm Capnia Inc. merged with closely held Essentialis Inc. in a stock swap to create a company organized around addressing rare diseases. Renamed Soleno Therapeutics with the new stock symbol (NASDAQ:SLNO), the firm is usefully understood as a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The firm's lead candidate - diazoxide choline controlled-release (DCCR) - is a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$219,917
Phase II Dollars
$2,076,167
Total Awarded
$2,296,084

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : SLNO
IP Holdings
50-74

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2018 2 NIH $2,296,084
Project Title: Point-Of-Care End-Tidal Carbon Monoxide Measurement to Screen for Sickle Cell Disease

Key People / Management

  Anish Bhatnagar -- Chief Executive Officer, President & Chief Operating Officer

  Neil Cowen -- Senior Vice President of Drug Development

  Edward A Ebbers -- Chief Commercial Officer and Sr. VP

  Jing Gong -- Head of Statistical Programming

  David O'Toole -- Chief Financial Officer

  Anthony D Wondka -- Vice President, Research And Development

  Kristen Yen -- Vice President, Clinical and Regulatory Affairs

Company News

Mar 08 2017
Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company
Jul 27 2015
Capnia Announces $10 Million At-the-Market Firm Commitment Stock Purchase Agreement with Aspire Capital
Nov 13 2014
Capnia, Inc. Announces Pricing of Initial Public Offering